On February 19, 2026, Cocrystal Pharma, Inc. (COCP) announced that initial data from the Phase 1b norovirus challenge study of CDI-988 will be presented at the 39th International Conference on Antiviral Research (ICAR2026). Dr. Sam Lee, Cocrystal's President and co-CEO, will discuss the design of the ongoing Phase 1b study, in which CDI-988 is being evaluated as both a preventative and treatment for norovirus infection. Dr. Lee will also present data from the company's Phase 1 clinical trial of CDI-988 that included both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Previously announced data showed that the drug was well tolerated across all doses tested. CDI-988 is the first oral antivirus drug candidate being developed for both the prevention and treatment of norovirus infection.
